Literature DB >> 24270780

Reply to miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection.

Markus Heim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24270780     DOI： 10.1038/nri3463-c2

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


× No keyword cloud information.
  11 in total

1.  miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection.

Authors:  Jae Il Shin; Michael Eisenhut
Journal:  Nat Rev Immunol       Date:  2013-12       Impact factor: 53.106

2.  Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α.

Authors:  Junli Hao; Wensong Jin; Xinghui Li; Saifeng Wang; Xiaojun Zhang; Hongxia Fan; Changfei Li; Lizhao Chen; Bin Gao; Guangze Liu; Songdong Meng
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

3.  Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

Authors:  Masao Honda; Akito Sakai; Tatsuya Yamashita; Yasunari Nakamoto; Eishiro Mizukoshi; Yoshio Sakai; Taro Yamashita; Mikiko Nakamura; Takayoshi Shirasaki; Katsuhisa Horimoto; Yasuhito Tanaka; Katsushi Tokunaga; Masashi Mizokami; Shuichi Kaneko
Journal:  Gastroenterology       Date:  2010-04-29       Impact factor: 22.682

4.  Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

Authors:  Limin Chen; Ivan Borozan; Jordan Feld; Jing Sun; Laura-Lee Tannis; Catalina Coltescu; Jenny Heathcote; Aled M Edwards; Ian D McGilvray
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

5.  Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

Authors:  Michael T Dill; Francois H T Duong; Julia E Vogt; Stéphanie Bibert; Pierre-Yves Bochud; Luigi Terracciano; Andreas Papassotiropoulos; Volker Roth; Markus H Heim
Journal:  Gastroenterology       Date:  2010-11-25       Impact factor: 22.682

Review 6.  25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end.

Authors:  Markus H Heim
Journal:  Nat Rev Immunol       Date:  2013-06-07       Impact factor: 53.106

7.  IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

Authors:  Thomas J Urban; Alexander J Thompson; Shelton S Bradrick; Jacques Fellay; Detlef Schuppan; Kenneth D Cronin; Linda Hong; Alexander McKenzie; Keyur Patel; Kevin V Shianna; John G McHutchison; David B Goldstein; Nezam Afdhal
Journal:  Hepatology       Date:  2010-10-07       Impact factor: 17.425

8.  Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.

Authors:  Tung-Hung Su; Chen-Hua Liu; Chun-Jen Liu; Chi-Ling Chen; Te-Tien Ting; Tai-Chung Tseng; Pei-Jer Chen; Jia-Horng Kao; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-23       Impact factor: 11.205

9.  Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  T Asselah; I Bieche; S Narguet; A Sabbagh; I Laurendeau; M-P Ripault; N Boyer; M Martinot-Peignoux; D Valla; M Vidaud; P Marcellin
Journal:  Gut       Date:  2007-09-25       Impact factor: 23.059

10.  Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy.

Authors:  Magdalena Sarasin-Filipowicz; Jacek Krol; Ilona Markiewicz; Markus H Heim; Witold Filipowicz
Journal:  Nat Med       Date:  2009-01-04       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.